Dr. Bierman on Unmet Needs for Patients With CNS Involvement in Aggressive NHL

Philip Bierman, MD
Published: Wednesday, Aug 08, 2018



Philip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses unmet needs for patients with central nervous system (CNS) involvement in aggressive subtypes of non–Hodgkin lymphoma (NHL).

There are many unmet needs for patients with CNS involvement in aggressive subtypes of NHL, and there have not been any randomized trials to date for this population, explains Bierman. Therefore, the best regimen to use in these patients is still up for debate. Additionally, the use of transplant is another area of question, though many physicians tend to recommend the procedure, says Bierman.

As far as regimens are concerned, the combination of ibrutinib (Imbruvica) and R-CHOP or lenalidomide (Revlimid) and R-CHOP may decrease the rate of CNS relapse. As it stands, most physicians believe that some sort of anthracycline-based therapy in combination with mid-cycle high-dose methotrexate is a good regimen to pursue for these patients, states Bierman.
SELECTED
LANGUAGE


Philip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses unmet needs for patients with central nervous system (CNS) involvement in aggressive subtypes of non–Hodgkin lymphoma (NHL).

There are many unmet needs for patients with CNS involvement in aggressive subtypes of NHL, and there have not been any randomized trials to date for this population, explains Bierman. Therefore, the best regimen to use in these patients is still up for debate. Additionally, the use of transplant is another area of question, though many physicians tend to recommend the procedure, says Bierman.

As far as regimens are concerned, the combination of ibrutinib (Imbruvica) and R-CHOP or lenalidomide (Revlimid) and R-CHOP may decrease the rate of CNS relapse. As it stands, most physicians believe that some sort of anthracycline-based therapy in combination with mid-cycle high-dose methotrexate is a good regimen to pursue for these patients, states Bierman.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x